OssiFi Overview
- Headquarters
- 11235 Mastin St
- Website
- www.ossifi.com
- Industry
- Biotechnology Research
- Employees
- 6
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
About OssiFi
OssiFi Therapeutics is developing market disruptive anti-sclerostin regenerative bone-biology products to address significant unmet needs in low back pain, fracture repair, and fracture prevention. OssiFi's Key value drivers: 1) Oral competitor to Amgen’s injectable anti-sclerostin mAb product (Evenity®), and 2) Anti-sclerostin small molecule competitor to Medtronic’s INFUSE orthobiologic. OssiFi is seeking investor capital and strategic partnerships to support its efforts to deliver best-in-class bone regenerative therapies to prevent and treat fractures in patients suffering from Osteogenesis Imperfecta, post-menopausal osteoporosis, and other fragile-bone disorders.
Compare Similar Companies to OssiFi
Osteogenics Biomedical, Inc.
Medical Device
Montrium
Software Development
Eccogene
Pharmaceutical Manufacturing
Orogen Therapeutics
Biotechnology Research
Cybership
Transportation, Logistics, Supply Chain And Storage
Heliona
Mental Health Care
OsteoGeneX, Inc
Biotechnology Research
Iron Prairie Ventures
Venture Capital And Private Equity Principals
Jessica Freeman HR
Human Resources Services
Osteogenix Inc
Biotechnology